NCT04488601

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL): A Prospective, Double-Blind, Placebo-Controlled Trial for Rapamycin in Healthy Individuals Assessing Safety and Efficacy in Reducing Aging Effects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 129 (actual)
• Sponsor: AgelessRx · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, placebo-controlled trial into the safety and efficacy in reducing clinical measures of aging in an older adult population.

Detailed description

A randomized, double-blind, placebo-controlled trial assessing the effects of low and high doses of intermittent Rapamycin on a weekly schedule. The researchers aim to establish a long-term safety profile, determine the long-term efficacy of Rapamycin in reducing clinical aging measures, and biochemical and physiological endpoints associated with declining health and aging in healthy older adults.

Conditions

• Aging

Interventions

Type	Name	Description
DRUG	Rapamycin	Rapamycin in 2 different dosage forms.
DRUG	Placebo	Placebo capsules

Timeline

• Start date: 2020-01-01
• Primary completion: 2023-12-30
• Completion: 2023-12-30
• First posted: 2020-07-28
• Last updated: 2024-01-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study